CION Ameerpet
The best brain tumour decisions are never made by one doctor alone. At CION, a neuro-oncology tumour board reviews your case together — so your plan is coordinated, guideline-based and made for healing, not billing.
A neuro-oncology tumour board is a regular meeting where the specialists who treat brain tumours sit down and review each patient's case together, before any treatment plan is finalised. Instead of one doctor deciding on their own, a whole group looks at your scans, your pathology, your molecular results and your overall health — and agrees on the best next step.
You may also hear it called a brain tumour multidisciplinary team (MDT) meeting. The word "multidisciplinary" simply means many different specialties in one room. It matters because brain tumour care sits at the crossroads of surgery, radiation, drug therapy and diagnosis — and no single doctor holds all of that expertise.
This "many experts, one plan" approach is the recommended standard for complex cancers under NCCN and EANO guidance. At CION, every brain tumour case is reviewed by our tumour board before treatment begins. This page is part of our wider guide to brain cancer and tumour care and links closely with our brain tumour treatment page.
National and international cancer guidelines specifically recommend that every complex brain tumour case be discussed by a multidisciplinary team before treatment starts. Studies of tumour-board review consistently link it with more guideline-concordant care and, for many cancers, changes to the originally proposed plan in a meaningful share of cases. (Source: NCCN Central Nervous System Cancers guidelines; EANO guidelines on adult diffuse gliomas.)
Brain tumour management is among the most complex in all of oncology. Four different decisions must line up — and each belongs to a different specialty. That is exactly why a tumour board exists.
How much of the tumour can be safely removed, and by what approach? This is a surgical judgement — weighed at CION in coordination with accredited neurosurgical partners, since our own panel does not include an in-house neurosurgeon. It shapes everything that follows.
Should radiation be used, and how should it be targeted to hit the tumour while sparing healthy brain? This is answered by the radiation oncologist, who plans precise IMRT/IGRT — delivered directly by CION's radiation oncology team.
Which drug therapy — and in what sequence — fits this exact tumour type and molecular profile? The medical oncologist decides, guided by markers such as IDH and MGMT, and manages treatment directly with regular monitoring.
What exactly is this tumour? A radiologist reads the MRI and a pathologist confirms the tissue type, WHO grade and molecular markers. Get this wrong and every downstream decision is built on shaky ground.
The tumour board is where these four questions are answered together, so they add up to a single coordinated plan — not four separate opinions.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
You deserve a clear, coordinated plan reviewed by multiple specialists together. We walk this journey with you — with transparent costs and no obligation to start.
The board brings together the specialists who plan and deliver your care. The exact mix is matched to your tumour type and situation, but the core roles are:
CION's wider network draws on 150+ years of combined experience and 17 oncologists, so the right expertise is available for your specific tumour. Learn more about the surgical side of care on our brain tumour surgery page.
The board works through your case in a set order, so nothing important is missed. Here is what happens behind the scenes before your plan is agreed:
Want your reports run through this process? Book a free consultation or call 18002028726.
Before any brain tumour plan is set, the board makes sure the molecular results are back. For a malignant brain tumour, these markers — all read from the same biopsy sample — can matter as much as the surgery itself. If they are missing, the board asks for them first.
IDH is the single most powerful prognostic marker in glioma. An IDH-mutant tumour generally grows more slowly and has a better outlook than an IDH wild-type tumour of the same grade. It shapes both the modern WHO name and the treatment conversation.
This marker separates an astrocytoma from an oligodendroglioma — two tumours that respond differently to chemotherapy. Testing for it prevents a tumour from being mislabelled, which would send the plan in the wrong direction.
MGMT is a DNA-repair gene. When it is "methylated" (switched off), the tumour is more sensitive to alkylating chemotherapy. Knowing MGMT status helps the medical oncologist predict how well chemotherapy is likely to work. CION arranges IDH, 1p/19q and MGMT testing as standard on every malignant glioma biopsy — in line with NCCN and EANO guidance.
Once the board agrees a plan, CION delivers most of it directly and coordinates the rest transparently. You always know who is doing what:
A tumour board often reviews your case more than once. After treatment, the first follow-up MRI can be hard to read — post-treatment inflammation (called pseudoprogression) can make a scan look worse than the tumour really is. An experienced multidisciplinary team recognises this and avoids changing the plan prematurely. (Source: NCCN Central Nervous System Cancers guidelines; EANO guidelines on adult diffuse gliomas.)
A tumour board second opinion is especially worthwhile if any of these apply to your situation:
CION offers a free written second opinion reviewed by our neuro-oncology tumour board, with no obligation to start treatment. Decisions here are made for healing, not billing. Explore the full brain cancer & tumour hub or the brain tumour treatment page, and learn about the surgical side on our brain tumour surgery page. Book your free consultation today.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable before surgery, or if molecular testing (IDH, 1p/19q, MGMT) was not done on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A neuro-oncology tumour board is a regular meeting where specialists who treat brain tumours review each patient's case together, before a treatment plan is finalised. Instead of one doctor deciding alone, the group looks at your MRI, your pathology and molecular results, and your overall health, then agrees on the best next step. The panel typically includes a medical oncologist, a radiation oncologist, a radiologist, a pathologist, and — for surgical questions — a neurosurgical partner. This "many experts, one plan" approach is the recommended standard for complex cancers under NCCN and EANO guidance, because brain tumour decisions rarely belong to a single specialty.
Brain tumour care sits at the crossroads of several specialties. Surgery decides how much tumour can be safely removed; radiation oncology decides how to target what remains; medical oncology chooses the right systemic drugs; a neuropathologist and radiologist confirm exactly what the tumour is. No single doctor holds all of that expertise. A multidisciplinary team lets each specialist contribute, challenges assumptions, and catches gaps — for example, a missing molecular test that would change the plan. Research consistently links tumour-board review to more guideline-concordant care. At CION, every brain tumour case is reviewed this way before treatment begins.
CION's brain tumour board brings together the specialists who deliver care directly — a medical oncologist (systemic therapy), a radiation oncologist (IMRT/IGRT planning), a radiologist (MRI interpretation), and a pathologist for the tissue and molecular diagnosis. Because CION's panel does not include an in-house neurosurgeon, any surgical question — from stereotactic biopsy to brain tumour surgery — is discussed in coordination with accredited neurosurgical partners. Supportive-care, rehabilitation and palliative-care input is added where relevant. The mix of specialists is matched to your specific tumour type and situation.
The board works through your case in a set order. First, the diagnosis is confirmed — MRI findings, the pathology report, and molecular markers such as IDH, 1p/19q and MGMT. Next, the tumour is characterised — its WHO grade, its exact type, and its location relative to speech and movement areas. Then the group weighs the options — the role of surgery, radiation and systemic therapy, in what sequence, and against national and international guidelines. Finally, your wishes and overall fitness are factored in. The output is a single, written, coordinated plan — not a menu of conflicting opinions.
No — a tumour board review is designed to make care faster and safer, not slower. Boards meet on a regular schedule, and urgent cases are prioritised. Reviewing a case together at the start usually prevents delay, because it avoids the back-and-forth of sequential referrals and stops a plan from starting on an incomplete diagnosis (for example, before molecular testing is back). If your situation is an emergency — such as a first seizure or rapid deterioration — stabilising treatment and imaging happen immediately, and the board reviews the definitive plan as soon as results allow.
Yes. A tumour board second opinion is one of the most valuable things you can request — especially before surgery, or if molecular testing (IDH, 1p/19q, MGMT) was not done on your biopsy. CION offers a free written second opinion: bring your MRI, biopsy report and any molecular results, and the panel will review them and tell you, in plain language, whether the proposed plan matches current guidelines and whether any tests are missing. There is no obligation to start treatment with us. This is particularly worthwhile if surgery, radiation and chemotherapy have not all been discussed as one coordinated plan.
Often, yes. A tumour board is not a one-time event. Your case may return to the board at key decision points — after surgery, when the final pathology and molecular results are in; after radiation and chemotherapy, to review response; and if a follow-up MRI changes, to separate true progression from treatment-related inflammation (pseudoprogression) before altering the plan. This ongoing review is central to how CION delivers brain tumour care and matches NCCN and EANO recommendations for high-grade gliomas and other complex tumours. If you want your reports reviewed, book a free consultation or call our helpline.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.